Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease

Author:

Benoit Anne1,Beran Jiri2,Devaster Jeanne-Marie3,Esen Meral4,Launay Odile5,Leroux-Roels Geert6,McElhaney Janet E.7,Oostvogels Lidia3,van Essen Gerrit A.8,Gaglani Manjusha9,Jackson Lisa A.10,Vesikari Timo11,Legrand Catherine1,Tibaldi Fabian3,Innis Bruce L.12,Dewé Walthère3

Affiliation:

1. Institut de Statistique, Biostatistique et Sciences Actuarielles, Université Catholique de Louvain, Louvain-la-Neuve, Belgium

2. Vaccination and Travel Medicine Centre, Poliklinika II, Hradec Králové, Czech Republic

3. GSK Vaccines, Rixensart, Belgium

4. Institut für Tropenmedizin, Universitätsklinikum Tübingen, Germany

5. Université Paris Descartes, Sorbonne Paris Cité; Assistance Publique Hôpitaux de Paris, Hôpital Cochin, CIC Cochin-Pasteur; Inserm, CIC 1417-REIVAC, Paris, France

6. Centre for Vaccinology, Ghent University and Hospital, Belgium

7. Alan M. McGavin Chair in Geriatrics Research, Department of Medicine, University of British Columbia, Vancouver, Canada

8. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands

9. Section of Pediatric Infectious Diseases, Baylor Scott and White Health, Texas A&M Health Science Center College of Medicine, Temple

10. Group Health Research Institute, Seattle, Washington

11. Vaccine Research Center, University of Tampere, Finland

12. GSK Vaccines, King of Prussia, Pennsylvania

Abstract

Background.  To investigate the relationship between hemagglutinin-inhibition (HI) antibody levels to the risk of influenza disease, we conducted a correlate of protection analysis using pooled data from previously published randomized trials. Methods.  Data on the occurrence of laboratory-confirmed influenza and HI levels pre- and postvaccination were analyzed from 4 datasets: 3 datasets included subjects aged <65 years who received inactivated trivalent influenza vaccine (TIV) or placebo, and 1 dataset included subjects aged ≥65 years who received AS03-adjuvanted TIV (AS03-TIV) or TIV. A logistic model was used to evaluate the relationship between the postvaccination titer of A/H3N2 HI antibodies and occurrence of A/H3N2 disease. We then built a receiver-operating characteristic curve to ide.jpegy a potential cutoff titer between protection and no protection. Results.  The baseline odds ratio of A/H3N2 disease was higher for subjects aged ≥65 years than <65 years and higher in seasons of strong epidemic intensity than moderate or low intensity. Including age and epidemic intensity as covariates, a 4-fold increase in titer was associated with a 2-fold decrease in the risk of A/H3N2 disease. Conclusions.  The modeling exercise confirmed a relationship between A/H3N2 disease and HI responses, but it did not allow an evaluation of the predictive power of the HI response.

Funder

GlaxoSmithKline Biologicals SA

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Reference15 articles.

1. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses;Hobson;J Hyg (Lond),1972

2. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial;Barrett;Lancet,2011

3. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children;Black;Pediatr Infect Dis J,2011

4. Methods for estimating serological correlates of protection;Siber;Dev Biol Stand,1997

5. H3N2v and other influenza epidemic risk based on age-specific estimates of sero-protection and contact network interactions;Skowronski;PLoS One,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3